TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Surgical explantation after TAVR failure: What cardiologists, and patients, should know

Redo TAVR is not always a feasible treatment option, researchers explained. TAVR explantation can be offered to a larger patient population. 

Thumbnail

Valve-in-valve TAVR a safe alternative for patients with failed bioprosthetic valves

The final decision between ViV TAVR and repeat SAVR, researchers said, should be based on multiple factors. 

Thumbnail

PCI before TAVR? New study provides answers, but questions remain

Researchers examined data from 17 different facilities, keeping a close eye on mortality and rehospitalization rates. 

New TAVR system for high-risk patients gains FDA approval

The system was specifically designed for patients who should avoid open-heart surgery.  

Thumbnail

AI model classifies patients by aortic stenosis severity, could improve AVR timing

The classifier was developed using imaging data from nearly 2,000 patients. 

Thumbnail

3 conditions associated with a higher stroke risk among TAVR patients

The new analysis, published in Current Problems in Cardiology, also explored the higher costs associated with post-TAVR stroke. 

New meta-analysis examines valve durability after 5 years among TAVR, SAVR patients

As TAVR and SAVR patients get younger, valve durability will continue to gain more and more importance.

Thumbnail

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine. 

Displaying 321 - 328 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup